Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF‐06463922) and Desmethyl Congeners
- 16 February 2016
- journal article
- research article
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 55 (11) , 3590-3595
Abstract
Lorlatinib (PF‐06463922) is an ALK/ROS1 inhibitor and is in clinical trials for the treatment of ALK positive or ROS1 positive NSCLC (i.e. specific subsets of NSCLC). One of the laboratory objectives for this molecule indicated that it would be desirable to advance a molecule which was CNS penetrant in order to treat brain metastases. From this perspective, a macrocyclic template was attractive for a number of reasons. In particular, this template reduces the number of rotatable bonds, provides the potential to shield polar surface area and reinforces binding through a restricted conformation. All of these features led to better permeability for the molecules of interest and thus increased the chance for better blood brain barrier penetration. With a CNS penetrant molecule, kinase selectivity is a key consideration particularly with regard to proteins such as TrkB, which are believed to influence cognitive function. Removal of the chiral benzylic methyl substituent from lorlatinib was perceived as not only a means to simplify synthetic complexity, but also as a strategy to further truncate the molecule of interest. Examination of the NMR of the desmethyl analogues revealed that the compound existed as a mixture of atropisomers, which proved separable by chiral SFC. The individual atropisomers were evaluated through a series of in vitro assays, and shown to have a favorable selectivity profile when compared to lorlatinib. The challenge to develop such a molecule lies in the rate at which the atropisomers interchange dictated by the energy barrier required to do this. Here, we describe the synthesis of the desmethyl macrocycles, conformational studies on the atropisomers, and the kinetics of the interconversion. In addition, the corresponding conformational studies on lorlatinib are reported providing a hypothesis for why a single diastereomer is observed when the chiral benzylic methyl group is introduced.Keywords
This publication has 46 references indexed in Scilit:
- Assessing Atropisomer Axial Chirality in Drug Discovery and DevelopmentJournal of Medicinal Chemistry, 2011
- Atroposelective Total Synthesis of Axially Chiral Biaryl Natural ProductsChemical Reviews, 2010
- PerhexilineCardiovascular Drug Reviews, 2007
- NEWSCRIPTSChemical & Engineering News, 2003
- Putting chirality to work: the strategy of chiral switchesNature Reviews Drug Discovery, 2002
- Chiral Inversion and Hydrolysis of Thalidomide: Mechanisms and Catalysis by Bases and Serum Albumin, and Chiral Stability of Teratogenic MetabolitesChemical Research in Toxicology, 1998
- Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomideChirality, 1995
- Recent Advances in Atropisomerism1983
- Toxicity and Teratogenicity of Optical Isomers of ThalidomideNature, 1967
- The Stereochemistry of Diphenyls and Analogous Compounds.Chemical Reviews, 1933